WOODSIDE, Calif. and LAUSANNE, Switzerland, June 21, 2022 /PRNewswire/ -- The Lausanne-based team of US investment firm, +ND Capital, today marked its second successful exit in the European biotechnology market as Belgian biotech company, Galapagos NV (Euronext &NASDAQ: GLPG), announced1 that it will acquire Dutch cell therapy company CellPoint. +ND Capital was the sole venture investor in CellPoint, a company dedicated to developing CAR-T therapies at the point-of-care.
Read more at prnewswire.com+ND Capital's European Investment Strategy Delivers Again as Sale of CellPoint to Galapagos Paves the Way for Disruptive Point-of-Care Cell Therapy Model for Cancer Patients
Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.
